Article Text

Download PDFPDF
Short term oral minocycline treatment of meibomianitis
  1. J D Aronowicz,
  2. W E Shine,
  3. D Oral,
  4. J M Vargas,
  5. J P McCulley
  1. Department of Ophthalmology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA
  1. Correspondence to: J P McCulley MD The University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-9057, USA; james.mcculley{at}


Aim: To evaluate the clinical impact, aqueous tear parameters, and meibomian gland morphology in patients with primary meibomianitis before, during, and 3 months after a course of oral minocycline.

Methods: 16 patients were prospectively enrolled, 11 male and five female (mean age 69 years old). Each patient received routine clinical evaluations before, after 3 months therapy, and at 6 month study follow up visit. The clinical appearance, tear volume, flow and turnover, evaporation, Schirmer I test, meibomian gland dropout, lissamine green staining, and bacteriology wer evaluated.

Results: Improvement was observed in clinical signs of meibomianitis at the second and third visits. Microbial culture findings improved. Decreased aqueous tear volume and flow, and increased evaporation rate range at 35–45% relative humidity (RH) (p<0.05) were also detected. Other related tear parameters did not change. Meibomian gland dropout showed no improvement.

Conclusions: 3 months of oral minocycline resulted in clinical improvements in all meibomianitis signs that persisted for at least 3 months after discontinuation despite decreased aqueous tear volume and flow with increased evaporation (35–45% RH). However, there was improvement in the turbidity of secretions. Short term minocycline therapy probably has efficacy in the management of meibomianitis that extends beyond eradication of bacteria.

  • RH, relative humidity
  • dry eye
  • meibomianitis
  • minocycline
  • RH, relative humidity
  • dry eye
  • meibomianitis
  • minocycline

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • The authors have no proprietary interest in any product or concept discussed in this paper.